ALG2

Across TCGA pan-cancer cohorts, ALG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALG2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ALG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALG2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, OV, and UCEC are the cancer types where ALG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.985	0.104	.024	24	view →
OV	DFS	Tertile	All	0.416	0.889	.049	8	view →
UCEC	DFS	Quartile	All	0.984	0.835	.010	4	view →
HNSC	OS	Tertile	All	0.956	1.000	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALG2–CCRCC (OS)

Open the CCRCC breakdown →